{
    "clinical_study": {
        "@rank": "53596", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose Ampion", 
                "arm_group_type": "Experimental", 
                "description": "4 mL Ampion"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "4 mL placebo"
            }, 
            {
                "arm_group_label": "High Dose Ampion", 
                "arm_group_type": "Experimental", 
                "description": "10 mL Ampion"
            }, 
            {
                "arm_group_label": "10 mL Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "10 ml Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy of two doses of Intra-Articular Injection of Ampion\u2122\n      in Adults with pain due to osteoarthritis of the knee."
        }, 
        "brief_title": "A Efficacy and Safety Study of Two Doses of Intra-Articular Injection of Ampion\u2122 in Adults With Pain Due to Osteoarthritis of the Knee", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis of the Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of\n      two Doses of Intra-Articular Injection of Ampion\u2122 in Adults with pain due to osteoarthritis\n      of the knee.\n\n      The primary trial objective is to evaluate the greater efficacy of 10 mL Ampion\u2122 versus 10\n      mL placebo than 4 mL Ampion\u2122 versus 4 mL placebo intra-articular (IA) injection in improving\n      knee pain, when applied to patients suffering from OA of the knee.\n\n      The secondary trial objective include: the evaluation of the safety of an intra-articular\n      injection of Ampion\u2122 when applied to patients suffering from OA of the knee, evaluation of\n      the efficacy of intra-articular injection of Ampion\u2122 and placebo on stiffness and function\n      when applied to patients suffering from OA of the knee and evaluation of responder status\n      defined by the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research\n      Society International (OMERACT-OARSI) Criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to provide written informed consent to participate in the study\n\n          -  Willing and able to comply with all study requirements and instructions of the site\n             study staff\n\n          -  Male or female, 40 years to 85 years old (inclusive)\n\n          -  Must be ambulatory\n\n          -  Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of\n             OA and supported by radiological evidence Kellgren Lawrence Grade II to IV) that is\n             not older than 6 months prior to the date of screening\n\n          -  Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on\n             the WOMAC Index 3.1 5-point Likert Pain Subscale) assessed at screening\n\n          -  Moderate to moderately-severe OA pain in the index knee (even if chronic doses of\n             nonsteroidal anti-inflammatory drug (NSAID), which have not changed in the 4 weeks\n             prior to screening, have been/are being used)\n\n          -  No analgesia (including acetaminophen [paracetamol]) taken 12 hours prior to an\n             efficacy measure\n\n          -  No known clinically significant liver abnormality e.g. cirrhosis, transplant, etc.)\n\n        Exclusion Criteria:\n\n          -  As a result of medical review and screening investigation, the Principal Investigator\n             considers the patient unfit for the study\n\n          -  A history of allergic reactions to human albumin (reaction to non-human albumin such\n             as egg albumin is not an exclusion criterion)\n\n          -  A history of allergic reactions to excipients in 5% human albumin\n             (N-acetyltryptophan, sodium caprylate)\n\n          -  Presence of tense effusions\n\n          -  Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis\n             or joint replacement in the affected knee, as assessed locally by the Principal\n             Investigator\n\n          -  Isolated patella femoral syndrome, also known as chondromalacia\n\n          -  Any other disease or condition interfering with the free use and evaluation of the\n             index knee for the duration of the trial e.g. cancer, congenital defects, spine OA)\n\n          -  Major injury to the index knee within the 12 months prior to screening\n\n          -  Severe hip OA ipsilateral to the index knee\n\n          -  Any pain that could interfere with the assessment of index knee pain (e.g. pain in\n             any other part of the lower extremities, pain radiating to the knee)\n\n          -  Any pharmacological or non-pharmacological treatment targeting OA started or changed\n             during the 4 weeks prior to randomization or likely to be changed during the duration\n             of the study\n\n          -  Use of the following medications:\n\n               1. No IA injected pain medications in the study knee during the study\n\n               2. No analgesics containing opioids. NSAIDs may be continued at levels preceding\n                  the study and acetaminophen is available as a rescue medication during the study\n                  from the provided supply\n\n               3. No topical treatment on osteoarthritis index knee during the study\n\n               4. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study\n                  (treatment such as Aspirin and Plavix are allowed)\n\n               5. No systemic treatments that may interfere with safety or efficacy assessments\n                  during the study\n\n               6. No immunosuppressants\n\n               7. No use of corticosteroids > 10 mg prednisolone equivalent per day (if \u2264 10 mg\n                  prednisolone, the dose must be stable)\n\n          -  Any human albumin treatment in the 3 months before randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839331", 
            "org_study_id": "AP-003-A"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low Dose Ampion", 
                "description": "4 mL Ampion", 
                "intervention_name": "Low Dose Ampion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High Dose Ampion", 
                "description": "10 mL Ampion 10mL", 
                "intervention_name": "High Dose Ampion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "4 mL Placebo", 
                "intervention_name": "Placebo Low Dose 4 mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "10 mL Placebo", 
                "description": "Placebo 10 mL", 
                "intervention_name": "Placebo 10 mL", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "osteoarthritis", 
            "osteoarthrisis of the knee"
        ], 
        "lastchanged_date": "December 22, 2013", 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of Intra-Articular Injection of Ampion\u2122 in Adults With Pain Due to Osteoarthritis of the Knee", 
        "overall_official": {
            "affiliation": "Ampio Pharmaceuticals. Inc.", 
            "last_name": "Vaughan Clift, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement in knee pain", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Improvement in stiffness and function, defined by the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (MERACT-OARSI) Criteria", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Ampio Pharmaceuticals. Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ampio Pharmaceuticals. Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}